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Background: Anticipating and controlling drug-drug interactions (DDIs) in older patients with painful diabetic
peripheral neuropaty (pDPN) presents a significant challenge to providers. The purpose of this study was to examine
the impact of newly initiated pregabalin or duloxetine treatment on Medicare Advantage Prescription Drug (MAPD)
plan pDPN patients’ encounters with potential drug-drug interactions, the healthcare cost and utilization consequences
of those interactions, and opioid utilization.
Methods: Study subjects required a pregabalin or duloxetine pharmacy claim between 07/01/2008-06/30/2012
(index event), ≥1 inpatient or ≥2 outpatient medical claims with pDPN diagnosis between 01/01/2008-12/31/
2012, and ≥12 months pre- and ≥6 post-index enrollment. Propensity score matching was used to balance the
pregabalin and duloxetine cohorts on pre-index demographics and comorbidities. Potential DDIs were defined by
Micromedex 2.0 and identified by prescription claims. Six-month post-index healthcare utilization (HCU) and costs
were calculated using pharmacy and medical claims.
Results: No significant differences in pre-index demographics or comorbidities were found between pregabalin
subjects (n = 446) and duloxetine subjects (n = 446). Potential DDI prevalence was significantly greater (p < 0.0001)
among duoxetine subjects (56.7%) than among pregabalin subjects (2.9%). There were no significant differences
in HCU or costs between pregablin subjects with and without a potential DDI. By contrast, duloxetine subjects
with a potential DDI had higher mean all-cause costs ($13,908 vs. $9,830; p = 0.001), more subjects with ≥1 inpatient
visits (35.6% vs 25.4%; p = 0.02), and more subjects with ≥1 emergency room visits (32.8% vs. 20.7%; p = 0.005) in
comparison to duloxetine subjects without a potential DDI. There was a trend toward a difference between pregabalin
and duloxetine subjects in their respective pre-versus-post differences in milligrams (mg) of morphine equivalents/
30 days used (60.2 mg and 176.9 mg, respectively; p = 0.058).
Conclusion: The significantly higher prevalence of potential DDIs and potential cost impact found in pDPN duloxetine
users, relative to pregabalin users, underscore the importance of considering DDIs when selecting a treatment.
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Challenging to patients, as well as providers, diabetes
has the potential to cause a specific group of nerve dis-
orders categorized as autonomic, peripheral proximal,
focal, and peripheral neuropathies [1,2]. A common
complication of diabetes, painful diabetic peripheral
neuropathy (pDPN) affects approximately 1 in 4 people
with this disease. Reduced glycemic control, advanced
age of the patient, and the length of time the patient has
diabetes are all documented risk factors for developing
pDPN [3-6]. Diagnosis of the condition involves docu-
mentation of the symptoms of peripheral nerve dysfunc-
tion after exclusion of other potential causes of pain.
The development of pDPN has been linked to signaling
impairment in the central nervous system, although the
process driving this change remains inadequately under-
stood [7,8].
While the advancement of pDPN has been shown to
be decreased through glycemic control [5], a variety of
treatment options are available for pDPN; however,
only a limited number have been proven effective in
appropriate clinical trial settings [9,10]. There are a
number of drug classes recommended and available in-
cluding anticonvulsants, tricyclic antidepressants, and
serotonin-norepinephrine reuptake inhibitors (SNRIs)
[9,11]. Guidelines are available for treatment of pDPN;
however, these can differ, and the recommended medi-
cations may generate adverse effects in conjunction
with diabetic treatments [11,12]. Only three drugs,
pregabalin, duloxetine, as well as the recently approved
tapentadol, have been approved by the Food and Drug
Administration for treatment of pDPN [13-20]. Evi-
dence has been put forth for the use of opioids such as
oxycodone and tramadol in treatment of pDPN through
randomized controlled trials, although there is no long-
term evidence of their impact on the disease or on
quality of life of patients [9,11,21-24]. Stemming from
the variable course of pDPN, the risk of opioid addiction
in this group is increased, and a number of side effects are
associated with opioids including hypogonadism and
lowered immunity [25-27]. Consequences of opioid
overdosing, especially in older patients, can be severe
and clinical decision-making must balance the risk of
such adverse effects by achieving pain control at the
lowest possible combined dose(s) of opioid [28]. Previ-
ous retrospective studies across various patient popula-
tions and utilizing disparate definitions of opioid
utilization have incongruent findings regarding the
opioid-sparing effects of pregabalin [29-32] and duloxe-
tine [29,30,33]. While clarity on the opioid-sparing ef-
fect of pregabalin and duloxetine should continue to be
sought, it must be done so in light of introducing po-
tential drug-drug interactions (DDIs) through use of
either agent.As the occurrence of pDPN increases with the degree
of hyperglycemia and age of the patient, the total num-
ber of prescriptions a patient may be taking has the po-
tential to rise dramatically due to the need to manage
the effects of advancing diabetes and comorbidities re-
lated to the disease. As such, anticipating and control-
ling DDIs in patients with pDPN presents a significant
challenge to providers, particularly in an older popula-
tion. The consequences of these drug interactions have
the potential to impact the quality of life of the patient,
as well as increase the cost of the disease [9,34].
While some studies have examined aspects of treat-
ment outcomes such as healthcare utilization and eco-
nomic comparisons between pregabalin and duloxetine
(where the costs were found to be comparable between
the two drugs), few studies have documented the costs
incurred from DDIs related to treatment of patients with
pDPN [29,34-36]. Recently, Johnston et al. [34] exam-
ined the frequency and financial impact of DDIs and
drug-condition interactions (DCIs) in predominantly
commercially-insured pDPN patients prescribed prega-
balin or duloxetine and found patients taking duloxetine
had a substantially higher potential for DDIs and DCIs
than patients taking pregabalin. Furthermore, the costs
associated with potential DDIs and DCIs in patients tak-
ing duloxetine were found to be significantly increased.
The present study continues and builds on previous
research by examining the impact of newly initiated
pregabalin or duloxetine treatment on Medicare Advan-
tage Prescription Drug plan (MAPD) pDPN members’
encounters with potential drug-drug interactions, the
healthcare cost and utilization consequences of those in-
teractions, and opioid utilization.
Methods
Study design and subject selection
This study is a retrospective, matched cohort study using
medical and pharmacy claims collected from a large
MAPD health plan. Medical and pharmacy claims data
were extracted for the period of time between January 1,
2007 and December 31, 2012, and these data were used
to identify potential subjects, measure patient character-
istics, and examine study outcomes. MAPD members di-
agnosed with DPN were identified as potential subjects
for the analysis based on International Classification of
Disease, 9th revision, Clinical Modification (ICD-9-CM)
diagnosis data reported on medical claims.
Members receiving pregabalin (Lyrica®) or duloxetine
(Cymbalta®) between January 1, 2008 and June 30, 2012
were identified based on pharmacy claims, and the first
observed prescription claim during this period was
assigned as the study index date. Tapentadol was not in-
cluded as a comparator as the study period did not allow
for sufficient sample size to analyze members prescribed
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have 12 months of continuous pre-index enrollment
during which no prescription claim for duloxetine or
pregabalin was observed.
In order to enhance the likelihood that the medication
of interest was being used to treat pDPN, it was further
required that a diagnosis of DPN be observed within
90 days of the index date. Subjects meeting any of the
following criteria were excluded from the study: Age <18
or >89 years; continuous enrollment <6 months post-
index; diagnosis of fibromyalgia (FM) at any time after
the index date; diagnosis and/or procedure code indicative
of transplant surgery, cancer, or pregnancy during study
period; long-term care facility residence of ≥90 days dur-
ing the study period; or, one or more prescription claims
for the non-index comparator drug (eg, if index drug is
duloxetine, then non-index comparator drug is prega-
balin) 12 months prior to or on the index date. The re-
search protocol was reviewed and approved by
Shulman Associates IRB, an independent Institutional
Review Board, prior to study initiation. A waiver of in-
formed consent and a waiver of authorization to use
protected health information (PHI) were granted.
Baseline measures
The subject’s assignment to either the pregabalin cohort
or the duloxetine cohort was determined by the medica-
tion filled on the subject’s index date. Age, gender, race/
ethnicity, geographic region of residence, low income
subsidy (LIS) status, and Medicare dual eligibility (DE)
status were measured based on member enrollment
data. The Deyo implementation of the Charlson comor-
bidity index score was calculated based on medical
claims adjudicated (insurer payment determined) during
the pre-index observation period [37,38]. In addition to
the Charlson score, specific pain-related medical condi-
tions of interest were identified based on ICD-9-CM
codes reported on medical claims during the pre-index
period.
Pre-index and post-index medication utilization were
measured based on pharmacy claims adjudicated during
their respective observation periods. Pain-related medi-
cation use patterns were measured for the following
medication classes: opioids, non-opioid analgesics, anti-
depressants, anticonvulsants, anesthetics, muscle relax-
ants, and anxiolytics. Individual subjects were identified
as medication users if they had one or more prescription
claims for the specific medication during the observation
period. Opioid use was further examined and catego-
rized as long-acting, short-acting low potency, and
short-acting high potency [39]. In addition, intensity of
opioid use was determined through conversion to mor-
phine equivalents (MEq) based on established conver-
sion factors [39]. The opioid dose strength and quantityof fill for each adjudicated opioid prescription claim was
converted to MEq, summed for the observation period,
and then normalized to an average MEq per 30 days.
Study outcomes
Drug-drug interaction status
Medications with high potential for drug-drug interac-
tions (DDI) with duloxetine or pregabalin (Table 1) were
identified based on a drug interaction report generated
from Micromedex 2.0 (Truven Health Analytics Inc.,
Greenwood Village, CO). Medications with an inter-
action classified as contraindicated, major, and moderate
were included as potentially interacting drugs of interest.
Medications with an interaction classified as minor or
unknown in the Micromedex 2.0 system were not in-
cluded as potentially interacting medications. Prescrip-
tion claims were used to identify subjects receiving
medication(s) that potentially interact with the index
medication.
Subjects were flagged with a DDI if they met either of
the following criteria: 1) a prescription claim for an
interacting medication during the pre-index period and
a corresponding days’ supply indicative of coverage that
overlapped the index date; or, 2) an adjudicated prescrip-
tion claim for an interacting medication filled within
30 days after the index date.
Healthcare resource utilization and costs
All-cause medical service utilization and costs were
measured using medical claims data. Medical claim place
of service was used to assign inpatient, emergency room,
and outpatient utilization and costs. Physical therapy
(PT) utilization was identified using medical claims
where the Current Procedural Terminology (CPT) code
billed indicated a physical therapy service was per-
formed. Total pharmacy costs were defined as the sum
of costs (plan-paid and member-paid) associated with
adjudicated pharmacy claims. Total all-cause healthcare
costs were defined as the sum of the respective total
medical cost and total pharmacy cost components. All
cost calculations included both member and plan paid
components, and were adjusted to 2012 United States
(US) dollars based on the medical care component of
the Consumer Price Index. Post-index opioid utilization
was determined both categorically and as MEq per
30 days, as previously described for the pre-index
period.
Analysis
Propensity score (PS) matching was utilized to address
potential bias in this non-randomized, observational
study [40,41]. In the PS matching, all baseline demo-
graphic characteristics and medical conditions of interest
were included. The PS matching process, matching a
Table 1 Pregabalin and duloxetine drug-drug interactions
Severity Brief description of potential harm due to DDI Interacting drug
Pregabalin
Major Reduced pregabalin effectiveness naproxen, ketorolac
Duloxetine
Contraindicated CNS toxicity or serotonin syndrome isocarboxazid, linezolid, procarbazine, rasagiline, selegiline, tranylcypromine
Increased serum concentrations of interacting drug
and risk of cardiac arrhythmia
thioridazine
Increased risk of extrapyramidal reactions or
neuroleptic malignant syndrome
metoclopramide
Increased risk of serotonin syndrome or neuroleptic
malignant syndrome-like reactions
methylene blue
Major Increased interacting drug plasma level and
Increased risk of QT prolongation
clozapine
Increased risk of bleeding antiplatelet agents, escitalopram
Increased risk of serotonin syndrome almotriptan, citalopram, cyclobenzaprine, desvenlafaxine, dextromethorphan,
eletriptan, fluoxetine, fluvoxamine, frovatriptan, hydroxytryptophan, lithium,
lorcaserin, methadone, milnacipran, naratriptan, paroxetine, rizatriptan, sertraline,
sumatriptan, tapentadol, tramadol, trazodone, tryptophan, venlafaxine, zolmitriptan
Increased risk of serotonin syndrome or neuroleptic
malignant syndrome-like reactions
vilazodone
Increased serum concentrations of interacting drugs
and an Increased risk of cardiotoxicity
class 1C antiarrhythmic agents
Moderate decreased plasma concentrations of the active
metabolites of interacting drug
tamoxifen
Increased duloxetine serum concentrations and risk
of adverse effects
ciprofloxacin, clobazam, enoxacin, mirabegron, quinidine
Increased exposere to interacting drug and
potential toxicity
phenothiazines, tamsulosin, tricyclic antidepressants
Increased risk of bleeding acenocoumarol, dabigatran, dalteparin, danaparoid, desirudin, enoxaparin,
fondaparinux, nonsteroidal anti-inflammatory agents, phenindione,
phenprocoumon, tinzaparin, warfarin
Source: Micromedex 2.0 (Truven Health Analytics Inc., Greenwood Village, CO), accessed May 31, 2013. Drugs with primary use in the hospital setting (e.g., lepirudin)
were excluded.
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on the nearest neighbor approach, without replacement,
using a caliper width of 0.005.
Diagnostic evaluation was considered to examine bal-
ance in pre-index covariates (from the propensity score
model) between matched treatment groups. In order to
account for the non-normal data distribution, continu-
ous pre-index measures were compared between-groups
using non-parametric Wilcoxon rank-sum tests. Chi-
square tests were used to compare categorical pre-index
data. Wilcoxon rank-sum test and chi-square tests were
also performed for post-index outcomes [42].
Multivariable statistical models were applied to exam-
ine the relationship between DDI status and healthcare
costs [43]. Specifically, a generalized linear mixed model
(GLMM) with a gamma distribution and log link was fit-
ted to model total healthcare costs. Several variables
were entered into the model. They included index drug,
DDI status, demographic characteristics, baseline med-
ical conditions, and pre-index medication utilization. An“index drug*DDI status” covariate interaction term was
also included in the model. Means and confidence inter-
vals were derived from the models and then retrans-
formed into dollar values through exponentiation of the
adjusted least square (LS) means estimates. All compari-
sons of total all-cause healthcare costs between and within
cohorts were assessed using Wald chi-square tests.
Differences in all-cause total healthcare costs were com-
pared between the cohorts (i.e., by pregabalin/duloxetine
and DDI status) via Difference-in-Differences (DID) ana-
lyses, using the model-based LS Means estimates and cor-
responding standard errors:
DID =mean of values in (DDI present minus DDI ab-
sent in the pregabalin cohort) minus mean of values in
(DDI present minus DDI absent in the duloxetine cohort).
T-tests were performed to formally test the DID values
for statistical significance.
Differences in pre-index and post-index opioid
utilization and MEq were compared between pregabalin
and duloxetine cohorts via DID analysis. The t-statistic
Table 2 Patient characteristics
Pregabalin Duloxetine
N = 446 N = 446
n % n % P value*
Age, years (categorical) 0.1304
18-29 0 0.0 0 0.0
30-39 7 1.6 1 0.2
40-49 27 6.1 26 5.8
50-59 73 16.4 86 19.3
60-69 144 32.3 159 35.7
70-79 150 33.6 126 28.3
80-89 45 10.1 48 10.8
Gender 0.5854
Male 185 41.5 177 39.7
Female 261 58.5 269 60.3
Race/Ethnicity 0.7265
White 363 81.4 353 79.1
Black 58 13.0 69 15.5
Hispanic 13 2.9 14 3.1
Other 12 2.7 10 2.2
Geographic Region 0.6759
Northeast 5 1.1 5 1.1
Midwest 78 17.5 78 17.5
South 338 75.5 333 74.7
West 25 5.6 30 6.7
Low Income Status 87 19.5 92 20.6 0.6814
Dual Eligibility Status 52 11.7 56 12.6 0.6759
Mean SD Mean SD
Age, years (continuous) 66.7 10.7 66.7 10.4 0.5924
Propensity Score 0.47 0.14 0.47 0.14 0.9931
*All P values for categorical variables calculated using chi -square tests. All
P values for continuous variables calculated using Wilcoxon rank-sum tests.
SD, Standard Deviation.
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a GLMM with a logit link and binary distribution, con-
trolling for baseline demographics, Deyo-Charlson co-
morbidity index, and pre- and post-index non-opioid
pain medication utilization. The t-statistic for the MEq
DID analysis was derived from a GLMM with an identity
link and a Gaussian distribution, controlling for baseline
demographics, Deyo-Charlson comorbidity index, and pre-
and post-index non-opioid pain medication utilization.
The MEq DID analysis covered opioid prescription claims
from 6-months pre-index to 6-months post-index.
All data analyses were conducted using SAS version
9.3/SAS Enterprise Guide 5.1. The a priori alpha level




A total of 1,320 subjects met the study inclusion and ex-
clusion criteria (pregabalin n = 570, duloxetine n = 750).
After conducting the propensity score matching proced-
ure, the analytic cohort consisted of 446 matched pairs
(892 total study subjects). The lack of statistically signifi-
cant differences between the matched cohorts on baseline
demographics (see Table 2) or pre-index comorbidity mea-
sures (see Table 3) provides evidence to support that the
matching process was successful. The predominantly
older composition of the study cohorts was confirmed as
both the pregabalin and duloxetine groups exhibited a
mean age of 66.7 years. The percentage of subjects with
a potential DDI was greater in the duloxetine group
compared to the pregabalin group (56.7%, n = 253 vs.
2.9%, n = 13, p < 0.001). There were 17 potential DDIs
involving pregabalin, all of which were of “Major” se-
verity. There were 649 potential DDIs involving duloxe-
tine, including 11 “Contraindicated” interactions and
453 “Major” interactions (Table 4).
Healthcare resource utilization
There were no significant differences in any form of
healthcare utilization between pregabalin subjects with
and without a potential DDI (see Table 5). Compared to
duloxetine subjects without a potential DDI, significantly
greater percentages of duloxetine subjects with a potential
DDI had at least one inpatient hospitalization and at least
one emergency room (ER) visit. Similarly, duloxetine sub-
jects with a potential DDI had significantly higher mean
numbers of visits per member for all-cause inpatient hos-
pitalizations, ER visits, and outpatient (non-physical ther-
apy) visits compared to those without a potential DDI.
Healthcare costs
There were no significant differences in all-cause health-
care costs, or component costs (eg, pharmacy), betweenpregabalin subjects with and without a potential DDI
(see Table 6). Conversely, duloxetine subjects with a po-
tential DDI exhibited significantly greater costs in com-
parison to duloxetine subjects without a potential DDI.
Among duloxetine subjects, all-cause total healthcare
costs were significantly higher for those with a potential
DDI than those without (means: $13,908 vs. $9,830; p =
0.001). The component healthcare costs of total medical,
inpatient-related, ER-related, and total pharmacy costs
were also significantly higher in duloxetine subjects with
a potential DDI compared to those without.
Model-adjusted healthcare costs
No significant differences were found in model-adjusted
mean all-cause healthcare costs for subjects with a po-
tential DDI versus those subjects without a potential
Table 3 Pre-index comorbid conditions
Pregabalin Duloxetine
N = 446 N = 446
n % n % P value*
Abdominal pain/cramping 106 23.8 107 24.0 0.9374
Anxiety disorder 57 12.8 57 12.8 1
Arthritis 186 41.7 198 44.4 0.4171
Back pain with neuropathic
involvement
123 27.6 126 28.3 0.8228
Causalgia and other painful
neuropathies
109 24.4 112 25.1 0.8160
Depression 77 17.3 71 15.9 0.5892
Diabetes 388 87.0 397 89.0 0.3537
Epilepsy 9 2.0 10 2.2 0.8166
Fatigue 133 29.8 136 30.5 0.8268
Irritable bowel syndrome 6 1.3 6 1.3 1
Migraine headache 9 2.0 10 2.2 0.8166
Muscle weakness 50 11.2 49 11.0 0.9151
Neck pain with neuropathic
involvement
36 8.1 42 9.4 0.4770
Other back pain 165 37.0 168 37.7 0.8355
Other mental disorders 1 0.2 1 0.2 **
Other musculoskeletal pain 333 74.7 338 75.8 0.6982
Other neck pain (spinal) 57 12.8 63 14.1 0.5560
Sleep disorders 111 24.9 114 25.6 0.8171
Substance abuse or dependence 57 12.8 59 13.2 0.8422
Tension headache 5 1.1 4 0.9 **
Thinking/memory loss 12 2.7 8 1.8 0.3657
Trigeminal nerve disorders 2 0.4 0 0.0 **
Mean SD Mean SD
Deyo-Charlson Comorbidity
Index score
2.6 2.2 2.7 2.2 0.3058
*All P values for categorical variables calculated using chi-square tests. All
P values for continuous variables calculated using Wilcoxon rank-sum tests.
**Expected Counts <5. Chi-square test may not be appropriate.
SD, Standard Deviation.
Table 4 Observed pregabalin and duloxetine drug-drug
interactions by severity and interacting drug




Total Major for pregabalin 17
Grand total for pregabalin 17
Duloxetine
Contraindicated metoclopramide 11
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respectively; p = 0.8159) or the duloxetine cohort
($39,445 vs. $36,424, respectively; p = 0.4208) (see Table 7).
In accordance with those findings, the DID analysis found
no significant difference in all-cause healthcare costs asso-
ciated with the presence of a potential DDI attributable to
the index medication (p = 0.8950).
Opioid utilization and morphine equivalents
The DID analyses for the associations of index medica-
tion with opioid utilization and morphine equivalents
utilization are described in Tables 8 and 9, respectively.
There was a trend toward a significant difference be-
tween pregabalin and duloxetine subjects in their re-
spective pre-versus-post differences in mean morphine
Table 4 Observed pregabalin and duloxetine drug-drug
interactions by severity and interacting drug (Continued)
Moderate butalbital 4
Total Moderate for duloxetine 185
Grand total for duloxetine 649
*Severity category according to Micromedex 2.0 (Truven Health Analytics Inc.,
Greenwood Village, CO), as of May 31, 2013.
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176.9 mg, respectively; p = 0.058]. The DID analysis of
pre-index and post-index opioid utilization, as defined
by one or more claims for long-acting, short-acting
less potent, and short-acting more potent opioids,
found no significant difference associated with the
index medication.
Discussion
The present study adds to the limited understanding of
potential DDI prevalence, as well as the healthcare cost
and utilization consequences of those interactions, in a
predominantly older MAPD patient population newly
initiated on pregabalin or duloxetine for the treatment
of pDPN.
This present study found that pDPN subjects initiating
treatment with pregabalin were significantly less likely to
encounter potential DDIs than patients initiating duloxe-
tine. The magnitude of DDI prevalence for duloxetine
patients observed (56.7%) is likely driven by factors in-
herent to the medication itself and by the population in




n = 433 n =
All-Cause Inpatient Visits
Members with Hospitalization 123 (28.4%) 1 (7
Hospitalizations Per Member, Mean (SD) 0.9 (2.8) 0.1
All-Cause Emergency Room Visits
Members with Visit 100 (23.1%) 3 (2
Visits per Member, Mean (SD) 0.5 (1.2) 0.6
All-Cause Outpatient Visits (non-physical therapy)
Members with Visit 427 (98.6%) 13
Visits per Member, Mean (SD) 14.6 (12.6) 12.8
All-Cause Physical Therapy Visits
Members with Visit 57 (13.2%) 2 (1
Visits per Member, Mean (SD) 0.8 (3.1) 0.3
*All P values for categorical variables calculated using Chi Square tests. All P values
**Expected Counts <5. Chi-square test may not be appropriate.
DDI, Drug-Drug Interaction.
SD, Standard Deviation.metabolism by cytochrome P-450 (CYP450) isoenzymes
2D6 and 1A2. Further, it inhibits isoenzymes 2D6 and
1A2 and is highly plasma protein bound resulting in
many potential DDIs with other medications [44]. Alter-
natively, pregabalin has minimal pharmacokinetic or
pharmacodynamic interactions with other medications
as signified in this study by the low prevalence of poten-
tial DDIs found (2.9%) [45]. The comorbidity burden
and associated medication use of the matched pDPN
pregabalin and duloxetine cohorts align with previous
studies of pDPN patients [29,34-36] and it has been
shown that pain treatment itself is an independent risk
factor for exposure to potential DDIs [46,47].
A recent study by Johnston et al. found the frequency
of potential contraindicated, major, and moderate DDIs
in DPN patients newly initiated on duloxetine to be
3.9%, 36.9%, and 33.8%, respectively [34]. Conversely, no
DPN patients newly initiated on pregabalin encountered
a potential DDI of any severity. Methodological varia-
tions between the aforementioned study [34] and
present study may explain the differences in reported
potential DDI prevalence, with the most noteworthy
variation being the insurance plan case-mix amongst the
study populations. The former study [34] was conducted
in a younger, predominantly commercially-insured
population while the present study was conducted in a
Medicare population with a mean age of 66.7 years for
the matched cohorts. This observation highlights the
age-related vulnerability to drug interactions experi-
enced by older patients [48,49].ratified by drug-drug interaction status
Duloxetine
I No DDI
sent DDI present present
13 P value* n = 193 n = 253 P value*
.7%) ** 49 (25.4%) 90 (35.6%) 0.0214
(0.3) 0.0897 0.5 (1.9) 1.3 (3.9) 0.0059
3.1%) ** 40 (20.7%) 83 (32.8%) 0.0047
(1.2) 0.8068 0.4 (1.0) 0.7 (1.2) 0.0035
(100.0%) ** 190 (98.4%) 250 (98.8%) **
(9.1) 0.7728 15.2 (13.6) 17.3 (11.1) 0.0044
5.4%) ** 33 (17.1%) 32 (12.6%) 0.1869
(0.9) 0.8733 1.0 (4.1) 0.9 (3.5) 0.2342
for continuous variables calculated using Wilcoxon Rank-Sum tests.
Table 6 6-month post-index all-cause healthcare costs and component costs stratified by drug-drug interaction status
Pregabalin Duloxetine
No DDI present DDI present P value* No DDI present DDI present P value*
n = 433 n = 13 n = 193 n = 253
All-Cause Total Healthcare Costs, Mean (SD) 11,085 (16,820) 8,470 (13,491) 0.2156 9,830 (14,351) 13,908 (20,254) 0.001
All-Cause Total Medical Costs, Mean (SD) 8,339 (16,20) 6,115 (13,461) 0.1835 7,550 (14,081) 10,311 (16,609) 0.0278
Outpatient-Related (non-physical therapy), Mean (SD) 2,819 (5,639) 1,944 (2,366) 0.7170 2,711 (4,392) 2,517 (3,999) 0.8396
Physical Therapy-Related, Mean (SD) 93 (385) 17.7 (64.0) 0.5499 98 (363) 103 (516) 0.2824
Inpatient-Related, Mean (SD) 4,082 (12,371) 3,722.5 (13,421.7) 0.1458 3,782 (12,713) 5,873 (13,965) 0.0201
ER-Related, Mean (SD) 248 (700) 217.6 (429.6) 0.9152 224 (675) 386 (900) 0.0061
All-Cause Total Pharmacy Costs, Mean (SD) 2,746 (3,213) 2,355.9 (2,686.5) 0.3120 2,280 (2,396) 3,597 (11,125) <0.0001
Costs in US Dallars ($).
*All P values for categorical variables calculated using chi-square tests. All P values for continuous variables calculated using Wilcoxon rank-sum tests.
DDI, Drug-Drug Interaction; SD, Standard Deviation.
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differences in post-initiation all-cause healthcare costs
for pDPN patients newly initiated on pregabalin or
duloxetine [29,36]. The present study endeavored to de-
termine the impact of potential pregabalin and duloxe-
tine DDIs on 6-month post-initiation costs. AmongTable 7 Model-based* 6-month post-index all-cause total
healthcare costs by index medication and DDI status and






No DDI present $31,878 $9,545 - $106,461
DDI present $33,942 $8,995 - $128,076
Difference** $2,064 -
P value 0.8159 -
Duloxetine
No DDI present $36,424 $10,847 - $122,314
DDI present $39,445 $11,904 - $130,702
Difference** $3,021 -





Statistical difference† p = 0.8950
*GLMM model with gamma distribution and log link. Model-based means,
standard errors, and confidence intervals were derived from model and
transformed into dollar values through exponentiation. All p values are calculated
using Wald chi square tests through LSMEANS option. Presence of potential DDI,
Drug used (duloxetine versus pregabalin), DDI*Drug interaction term, baseline
demographic characteristics, baseline comorbidities present, and pre-index
medication utilization controlled for in GLM model.
**Represents the additional healthcare costs associated with the presence of a
potential DDI.
† t-test, utilizing model estimates, comparing pregabalin difference (DDI minus
No DDI) to duloxetine difference (DDI minus No DDI).
DDI, Drug-Drug Interaction.
CI, Confidence Interval.duloxetine subjects, mean all-cause total healthcare, total
medical, inpatient-related, emergency room, and total
pharmacy costs were significantly higher for those with a
potential DDI than those without. Non-statistically sig-
nificant cost increases were found between the pregaba-
lin members with and without a potential DDI. These
findings are substantiated by the Johnston et al. study
that found the combined presence of potential DDIs and
potential drug-condition interactions (DCIs) were asso-
ciated with significantly higher all-cause healthcare costs
in duloxetine users but not so in pregabalin users [34].
The non-significant findings of the within-pregabalin
cohort comparisons and in the difference-in-difference
analysis must be tempered by the small number of preg-
abalin subjects with a potential DDI (n = 13). The in-
crease in costs associated with potential DDIs within the
duloxetine cohort, however, cannot be overlooked. Prior
studies of chronic pain conditions have found that
CYP450 interactions between specific opioids (codeine,
fentanyl, hydrocodone, methadone, oxycodone, and
tramadol) and concomitant medications that serve as
substrates or inhibitors of CYP450 isoenzymes 3A4 and
2D6, including duloxetine, result in higher costs and
greater healthcare utilization [50-52].
A retrospective analysis of 170,086 patients using
claims data from 2004 to 2008 found significantly higher
mean total 6-month costs in chronic pain subjects with
an exposure to a potential DDI compared to matched
subjects without an exposure ($8165 vs. $7498, respect-
ively; p < 0.01) [50]. This same study found that potential
DDI exposed patients versus non-exposed patients ex-
perienced significantly more office visits (19.10 vs
18.29; p < 0.01), outpatient visits (6.71 vs 6.39; p < 0.01),
emergency department visits (0.46 vs 0.43; p < 0.01),
and inpatient hospitalizations (0.13 vs 0.12; p < 0.01)
[50]. The large sample sizes allowed for detection of
small differences, making the statistically significant
findings difficult to interpret in terms of clinical
Table 8 Opioid utilization* in pre- and post-index
6-month periods and difference-in-difference comparison











Pre-index 7.8 51.6 15.7
Post-index 10.1 53.8 17.5
Difference +2.2 +2.2 +1.8
Duloxetine
Pre-index 7.0 49.6 16.6
Post-index 10.1 50.9 19.3





2.2 versus 1.3 1.8 versus 2.7






*Defined as one or more opioid prescription fills during period.
**Difference in Difference t-statistic derived from a generalized linear mixed
model with a logit link and binary distribution adjusting for baseline demographics,
Deyo-Charlson comorbidity index, and pre- and post-index non-opioid pain
medication utilization.
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presence of potential DDI exposure is directionally con-
sistent with the duloxetine cohort in the present study
with regard to percent of patients with inpatient
hospitalization and ER visits and mean numbers of
visits per member for inpatient hospitalizations, ER
visits, and non-physical therapy outpatient visits.Table 9 Morphine equivalents utilization in pre- and
post-index 6-month periods and difference-in-difference













Difference-in-difference comparison* 60.2 vs. 176.9
Statistical difference* t = −1.90, p = 0.058
*Difference in Difference t-statistic derived from a generalized linear mixed
model with an identity link and a Gaussian distribution adjusting for baseline
demographics, Deyo-Charlson comorbidity index, and pre- and post-index
non-opioid pain medication utilization.Changes in opioid utilization after initiation of prega-
balin or duloxetine, regardless of potential DDI occur-
rence, were also assessed in the present study. No
changes in pre- to post-initiation of long-acting opioid,
short-acting opioid, strong opioid, weak opioid, or “any”
opioid use were found for pregabalin or duloxetine, as
defined by the percentage of patients with one or more
pharmacy claims, in the lone head-to-head retrospective
analysis of these drugs in a pDPN population [29]. How-
ever, when defined as the number of prescriptions filled
by opioid users, both pregabalin and duloxetine patients
experienced statistically significant increases in mean
number of prescriptions filled for short-acting, weak,
and “any” opioids [29]. Duloxetine patients also exhib-
ited significantly greater post-index use of long-acting
opioids [29]. The difference between the increases ob-
served for pregabalin and duloxetine were not com-
pared. As in the aforementioned study [29], the present
study found no difference between pregabalin and
duloxetine patients in their respective pre-versus-post
differences in the percentage of members with ≥1 phar-
macy claims for long-acting opioids, short-acting more
potent opioids, or short-acting less potent opioids.
Given that opioids within the same category, such as
“long-acting,” vary in terms of potency, the present study
expanded on the aforementioned research [29] by asses-
sing opioid use as a function of morphine equivalents. A
robust difference-in-difference analysis of 6-month pre-
index and 6-month post-index morphine equivalents
used identified a trend toward greater mean morphine
equivalents per 30-day post-index increase in use in the
duloxetine cohort relative to the pregabalin cohort
(176.9 mg vs. 60.2 mg, respectively; p = 0.058). As opi-
oids vary not only in duration of action but also in po-
tency, this finding, while not providing clarity on the
opioid-sparing differences of pregabalin compared to
duloxetine, does support the use of morphine equiva-
lents as a preferred method of comparing changes in
opioid utilization.
Several limitations must be noted for studies involving
administrative claims data. Causal effect cannot be
assigned given the observational nature of this study.
The use of secondary data is limited by the threat of val-
idity posed by inaccurate data within healthcare infor-
mation technology systems as well as by differences in
coding and documentation practices at the provider, re-
gion, or site-specific level. Actual patient behaviors re-
garding medication consumption cannot be assessed
through paid pharmacy claims. Further, reliance on paid
pharmacy claims for medication utilization does not cap-
ture the use of over-the-counter medications or remed-
ies impactful to the disease state in question. Indirect
costs were not considered as part of this study. A reduc-
tion in confounding was attempted through the use of
Ellis et al. BMC Health Services Research  (2015) 15:159 Page 10 of 11propensity score matching and multivariate modeling.
These approaches are limited by only the covariates in-
cluded in the statistical models. Even with this attempt
at bias reduction, residual confounding from included
covariates can still occur and confounding from un-
known or unmeasured covariates remains a possibility.
The use of “potential” DDIs does not imply the actual
occurrence of clinically-impactful DDIs, and therefore
limits the interpretation and applicability of the findings.
Lastly, given the focus on pDPN patients, the results of
this study should not be considered generalizable to
other FDA-approved indications or off-label uses.
Conclusion
The results of this retrospective analysis suggest that the
real-world prevalence of potential duloxetine DDIs in a
MAPD pDPN population is substantially greater than
that of potential pregabalin DDIs. While it is desirable to
find infrequent DDIs, the low prevalence of potential
pregabalin DDIs places limits on both the performance
and sensitivity of within or between drug comparisons.
From a clinical perspective, the importance of consider-
ing DDIs during treatment selection should be consid-
ered due to the significantly higher prevalence of
potential DDIs found in pDPN duloxetine users.
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